Journals / Erciyes Tıp Dergisi / 2007 / Cilt: 29 - Sayı: 6

Primary hepatic amyloidosis: Clinical features and pathologic findings in six cases

Primer hepatik amiloidozis: Altı olgunun klinik ve patolojik özelliklerinin değerlendirilmesi

Pages
451–455
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median survival of the five cases was 3,6 months.Conclusion: Amyloidosis should be remembered in differential diagnosis of elevated liver enzymes and hepatomegaly.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amyloidosis is characterized by extracellular deposition of insoluble fibrillar monoclonal light chains that may involve several organs.
📊
Key Findings & Data:We present clinical and pathological features of six cases with primary hepatic amyloidosis.Material and Methods: We reviewed the clinical features and pathologic findings of six patients with primary hepatic amyloidosis which were evaluated at Erciyes University Medical Faculty Department of Pathology from 1997 to 2006.
💡
Conclusion & Impact:The median survival of the five cases was 3,6 months.Conclusion: Amyloidosis should be remembered in differential diagnosis of elevated liver enzymes and hepatomegaly.
🔬Design:Review & Systematic Survey
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Amyloidosis is characterized by extracellular deposition of insoluble fibrillar monoclonal light chains that may involve several organs. While the liver is commonly involved in systemic amyloidosis, primary hepatic amyloidosis is very rare. We present clinical and pathological features of six cases with primary hepatic amyloidosis.Material and Methods: We reviewed the clinical features and pathologic findings of six patients with primary hepatic amyloidosis which were evaluated at Erciyes University Medical Faculty Department of Pathology from 1997 to 2006. The medical records were reviewed and histochemical and immunoperoxidase stains were performed on the tissue.Result: The median age of patients (4 (%67) men; 2 (%33) women) were 59,8 years. One patient’s biopsy was performed at postmortem. Hepatomegaly was found in two patients. Two of the patients had solitary liver nodules. One patient had ascites and another one had elevated serum alkaline phosphatase levels. Liver biopsies revealed massive deposit of an eosinophilic material replacing liver parenchyma. Congo red stains of the biopsies were positive for amyloid. Immunohistochemically Amyloid A, Kappa and Lambda were performed. There was no evidence of involvement of kidney and bone marrow. The median survival of the five cases was 3,6 months.Conclusion: Amyloidosis should be remembered in differential diagnosis of elevated liver enzymes and hepatomegaly.

Özet

Amiloidozis, fibriler bir protein olan amiloidin çeşitli organ ve dokularda ekstrasellüler birikimi ile karakterize bir hastalıktır. Sistemik amiloidozisde karaciğer tutulumu sıklıkla görülmekle birlikte primer hepatik amiloidozis oldukça nadirdir. Bu çalışmada, primer hepatik amiloidozis olan altı olgunun klinik ve patolojik özelliklerini değerlendirerek sunduk.Gereç ve Yöntemler: Çalışmamızda 1997-2006 yılları arasında Erciyes Üniversitesi Tıp Fakültesi Patoloji Anabilim dalında biyopsi ile primer hepatik amiloidozis tanısı alan altı olgu değerlendirildi. Tüm olguların klinik özellikleri gözden geçirildi. Doku kesitlerinin tamamına histokimyasal ve immünohistokimyasal yöntemler uygulandı. Bulgular: Dördü erkek (%67), ikisi kadın (%33) olan altı olgunun yaş ortalaması 59,8 idi. Bu olgulardan birinin biyopsisi postmortem olarak alınmıştı. Olgulardan ikisinde biyopsi alınma nedeni hepatomegali, ikisinde hepatosellüler karsinom şüphesi, birinde asit ve sarılık, bir olguda ise sebebi açıklanamayan karaciğer enzim yüksekliği idi. Yapılan karaciğer biyopsisinde sinüzoidleri dolduran, eozinofilik materyal birikim görülmekteydi. Bu birikim Kongo kırmızısı ile amilodi yönünde boyandı. İmmünohistokimyasal olarak Amyloid A, Kappa ve Lambda uygulandı. Olguların hiç birinde sistemik bulgu yoktu. Tamamı primer hepatik amiloidozis olarak kabul edildi. Biyopsi yapılan beş olgunun amiloidozis tanısı aldıktan sonraki ortalama yaşam süresi 3,6 aydı.Sonuç:Hepatomegali ve karaciğer enzim yüksekliği nedeniyle başvuran hastalarda klinik ve patolojik olarak ayırıcı tanıda amiloidozis akla getirilmelidir

🔖

Cite This Article

YURCİ, A., SOYUER, I., PATIROĞLU, T. E., AKGÜN, H. (2022). Primary hepatic amyloidosis: Clinical features and pathologic findings in six cases. Erciyes Tıp Dergisi, Cilt: 29 - Sayı: 6, 451–455. https://ajindex.com/articles/502717

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Abbas AK. Diseases of immunity. In: Kumar V, Abbas AK, Fausto N, editors. Robbins and Cotran Pathologic Basis of Disease. 7th edition. Philadelphia: Elsevier Saunders Company; 2004. p. 258-264
  2. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004; 255: 159-178
  3. Merrimen JL, Alkhudair WK, Gupta R. Localized amyloidosis of the urinary tract: case series of nine patients. Urology 2006; 67: 904-909
  4. Buck FS, Koss MN. Hepatic amyloidosis: morphologic differences between systemic AL and AA types. Hum Pathol 1991;22:904-907
  5. Gertz MA, Kyle RA. Hepatic amyloidosis: Clinical appraisal in 77 patients. Hepatology 1997; 25: 118–121
  6. Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): The natural history in 80 patients. Am J Med 1988; 85: 73–80
  7. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 2003; 82: 291-298
  8. Kim SH, Han JK, Lee KH, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol 2003; 58: 610-620
  9. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59
  10. Kyle RA, Greipp PR. Amyloidosis (AL): Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665–683
  11. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med. 1993;118:96–98
  12. Kitamura Y, Yokomori H. Hepatic amyloidosis manifesting severe intrahepatic cholestasis. Intern Med 2005; 44: 675-676
  13. Koklu S, Odemis B, Cengiz C, Yuksel O, Uskudar O, Turhan N. Fulminant hepatic failure due to secondary amyloidosis. Dig Liver Dis 2006; 38:208-210
  14. Agaram N, Shia J, Klimstra DS, et al. Globular hepatic amyloid: a diagnostic peculiarity that bears clinical significance. Hum Pathol 2005; 36: 845-849
  15. Looi LM, Sumithran E. Morphologic differences in the pattern of liver infiltration between systemic AL and AA amyloidosis. Hum Pathol 1988; 19: 732-735
  16. Chopra S, Rubinow A, Koff RS, Cohen AS. Hepatic amyloidosis. A histopathologic analysis of primary (AL) and secondary (AA) forms. Am J Pathol 1984; 115: 186-193
  17. Şen S, Ertan Y, Başdemir G. Renal amiloid birikiminin tayininde Kongo kırmızısı flöresansı. Türk Patoloji Dergisi 2002; 17: 28-33.